Novaliq is a pharmaceutical company committed to develop best-in-class ocular therapies.
Our unique and versatile water-free technology is poised to transform established treatments. Our team of seasoned industry experts is driven by the single mission:
Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA.
The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies.
Our journey started with NovaTears®, the first water-free eye drop based on EyeSol® for the treatment of dry eye. Novatears® is CE certified since 2014 and successfully commercialized in Australia/New Zealand and in Europe by our partners.
With an initial focus on dry eye disease we are now expanding into other eye care indications and topical therapeutics spaces.
Our team of seasoned industry experts explores the world of water-free therapies to develop best-in-class ocular therapies. We expand into other eye care indications and topical therapeutics spaces.
We work with leading academic and industry partners around the globe to bring innovative therapies leveraging our proprietary water-free technology to patients:
In December 2019 Bausch Health has acquired an exclusive license for the commercialization and development in the United States and Canada of the investigational treatment NOV03 (perfluorohexyloctane)
NOV03 is a first-in-class investigational drug with a novel mechanism of action to treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD). Three phase 3 studies are underway for NOV03 in the U.S. expecting to complete the clinical development.
In November 2019, Novaliq established a strategic cooperation with Jiangsu Hengrui Medicine.
Hengrui has received exclusive rights to develop, manufacture and commercialize NOV03 and CyclASol® in China.
In April 2019, Novaliq has founded Betaliq Inc., Tampa USA in collaboration with BLP Management Group, LLC.
Betaliq develops beta-blockers for Glaucoma treatment, using Novaliq’s water-free EyeSol® technology. A phase 2 clinical trial is underway to evaluate two preservative-free and water-free glaucoma drug candidates based on the EyeSol® technology.
Novaliq has a European Partnership Agreement with Ursapharm Arzneimittel GmbH, one of the leading EU ophthalmic players.
In October 2015, NovaTears® entered the EU market under Ursapharm’s brand name EvoTears®. Since then, EvoTears® has been successfully launched in 16 EU countries.
NovaTears®+Omega-3 has been recently launched in Germany and other European markets under Ursapharm’s brand name EvoTears® OMEGA.
Novaliq has a strategic Licensing Partnership Agreement with AFT Pharmaceuticals, a New Zealand-based pharmaceutical company (ASX, NZX)
AFT commercializes NovaTears® and NovaTears®+Omega-3 in Australia and New Zealand.
Novaliq collaborates with leading scientific partners
Prof. Dr. med. Claus Cursiefen and Prof. Dr. med. Philipp Steven in the field of ophthalmic drug delivery for the anterior segment of the eye with special focus on dry eye disease.
Prof. Heping Xu, MD, PhD, in the field of retina diseases.
Dr. Ilva Rupenthal in the field of drug delivery technologies and ocular therapeutics.
Prof. Dr. med. Johannes Wohlrab in the field of penetration and dermatology.
Prof. Dr. Wolfgang Frieß in the field of protein formulation.
Prof. Gordon Tiddy and Dr. Robin Curtis in the field of basic research in formulation sciences.